The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis-Reference-Cited by-同舟云学术

The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis

Published:2023-09-28 Issue:11 Volume:16 Page:1141-1152
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Xu Ke¹²^ORCID,Wang Tianlei¹,Pan Shenbin¹,He Jie¹³^ORCID

Affiliation:

1. Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China

2. Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China

3. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China

Funder

Natural Science Foundation of Sichuan Province

Foundation of Key Clinical Specialty of Sichuan Province

School Foundation of Chengdu Medical College

Project of Chengdu Medical Research

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2023.2262673

Reference60 articles.

1. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy

4. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes

5. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

2. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer;Medicine;2024-05-17